Update regarding CEO - Peter Sargent

15 May 2026

Physiomics plc

("Physiomics" or the "Company")

Update regarding CEO - Peter Sargent

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that Peter Sargent has agreed to extend his existing agreement with the Company and remain in his current role throughout June 2026. 

The Board and Dr Sargent remain in ongoing discussions regarding a potentially longer-term continuation of his involvement, in relation to which further updates will be provided in due course.

The Board acknowledges Dr Sargent's professionalism and contribution during a period of considerable change within the business and looks forward to continuing what has become a productive working relationship.

Nick Tulloch, Chairman of Physiomics plc, commented: "In the short time we have worked with Pete, he has diligently overseen the operations of Physiomics and, in particular, has handled the management transition of the business with evident skill and sensitivity. Pete has been a considerable support to the new Board and we are delighted that he is willing to continue in his role for the time being whilst we develop plans for growth and expansion of the Company."

ENDS

For more information about Physiomics and its services, please visit www.physiomics.co.uk.

Enquiries:

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting- edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 140 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.